Publications by authors named "Ilan Goldenberg"

Background: There are limited data on clinical and arrhythmic outcomes after a first ventricular tachyarrhythmia (VTA) in heart failure (HF) patients who receive a primary prevention implantable cardioverter-defibrillator (ICD).

Objective: This study was designed to quantify the burden of and to identify risk factors for recurrent VTA in this population and to evaluate the risk of all-cause mortality associated with recurrent VTA.

Methods: The study comprised 789 patients who experienced VTA following primary prevention ICD implantation in 5 ICD trials (MADIT-II, MADIT-RISK, MADIT-CRT, MADIT-RIT, RAID).

View Article and Find Full Text PDF

Introduction: The implantable cardioverter defibrillator reduces mortality among patients with heart failure (HF) due to ischemic heart disease. Clinical trial data have called into question the benefit of an ICD in patients with HF due to nonischemic cardiomyopathy (NICM). We developed a risk stratification score for ventricular tachyarrhythmia (VTA) among patients with NICM receiving a primary prevention ICD.

View Article and Find Full Text PDF

Background And Aims: Long QT syndrome (LQTS) and coronary artery disease (CAD) are both associated with increased risk of ventricular tachyarrhythmia However, there are limited data on the incremental risk conferred by CAD in adult patients with congenital LQTS. We aimed to investigate the risk associated with CAD and life threatening events (LTEs) in patients with LQTS after age 40 years.

Methods: The risk of LTEs (comprising aborted cardiac arrest, sudden cardiac death, or appropriate defibrillator shock) from age 40 through 75 years was examined in 1,020 subjects from the Rochester LQTS registry, categorized to CAD ( = 137) or no-CAD ( = 883) subgroups.

View Article and Find Full Text PDF
Article Synopsis
  • * Scoring systems like the MADIT Risk Stratification Score (MRSS) and Seattle Heart Failure Model (SHFM) help identify which patients might have better survival benefits from ICDs, based on studies involving real-world heart failure patients.
  • * Although these scoring systems aren't fully ready for clinical use, they can inform decisions on ICD implantation, especially for high-risk elderly patients or those with multiple health issues, while cardiac MRI can identify heart scar areas linked to arrhythmias.
View Article and Find Full Text PDF

Background: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown.

Methods: The National Institutes of Health-funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022.

View Article and Find Full Text PDF
Article Synopsis
  • Lymphoma treatment, particularly with Bruton tyrosine kinase inhibitors (BTKi), significantly increases the risk of developing new-onset atrial fibrillation (AF) compared to other treatments or no treatment.
  • In a study with nearly 2,000 lymphoma patients, the 5-year rate of AF was found to be 25% for those on BTKi, compared to only 8% for non-BTKi treatments and 4% for untreated patients.
  • Additionally, new cases of AF were linked to higher mortality risk, highlighting the importance of monitoring for AF in lymphoma patients, especially those with additional risk factors like older age and hypertension.
View Article and Find Full Text PDF
Article Synopsis
  • Some studies indicate that digoxin may lead to adverse health outcomes, including higher mortality rates in heart failure patients.
  • This study aimed to determine if digoxin increases the risk of ventricular tachycardia (VT) or ventricular fibrillation (VF) in heart failure patients with implantable cardioverter-defibrillators (ICDs).
  • The results showed that digoxin use significantly raised the risk of VT/VF by 48%, increased the risk of death by 37%, and led to more ICD shocks, highlighting potential dangers of digoxin in this patient group.
View Article and Find Full Text PDF

Introduction: Heart failure patients with a history of atrial fibrillation (AF) and ventricular tachycardia/ventricular fibrillation (VT/VF) are known to have worse outcomes. However, there are limited data on the temporal relationship between development of these arrhythmias and the risk of subsequent congestive heart failure (CHF) exacerbation and death.

Methods: The study cohort comprised 5511 patients implanted with an implantable cardioverter-defibrillator (ICD) in landmark clinical trials (MADIT-II, MADIT-RISK, MADIT-CRT, MADIT-RIT, and RAID) who were in sinus rhythm at enrollment.

View Article and Find Full Text PDF

Background: Recent studies suggest that participation in recreational and even competitive sports is generally safe for patients with implantable cardioverter-defibrillators (ICDs). However, these studies included only patients with implanted transvenous ICD (TV-ICD). Nowadays, subcutaneous ICD (S-ICD) is a safe and effective alternative and is increasingly implanted in younger ICD candidates.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of wearable cardioverter defibrillators (WCD) in patients at risk for sudden cardiac death, especially those with a history of atrial fibrillation (AF).
  • It was found that patients with prior AF have a significantly higher rate of ventricular and atrial arrhythmias while using the WCD compared to those without AF.
  • The findings suggest that the higher incidence of arrhythmias in AF patients could aid in making decisions about implantable cardioverter-defibrillator (ICD) placement.
View Article and Find Full Text PDF

Background: Sex-specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life-threatening events (LTEs) in postadolescent women with LQTS. In the present study, we aimed to develop personalized risk estimates for the burden of CEs and LTEs in male adolescents with potassium channel-mediated LQTS.

View Article and Find Full Text PDF

The risk of sudden cardiac death (SCD) in patients with cancer receiving cancer therapies is not well defined. In this study we aimed to (1) evaluate the risk of SCD during the first 6 months of cancer treatment and (2) identify risk factors (RFs) for SCD in patients who underwent active cancer treatment. The study population comprised 8,356 patients who received any cancer treatment at the University of Rochester Medical Center from 2011 to 2020.

View Article and Find Full Text PDF
Article Synopsis
  • This study analyzed sex differences in life-threatening heart conditions (ventricular tachycardia and ventricular fibrillation) among patients with implantable cardioverter-defibrillators (ICDs) who had previously experienced these issues.
  • Results showed that women had a significantly lower risk of these events and death compared to men, as well as a reduced risk of recurrent VT/VF.
  • Additionally, racial disparities were noted, with White women showing a much lower risk compared to White men, while Black women had similar risks to Black men.
View Article and Find Full Text PDF
Article Synopsis
  • Current guidelines recommend implantable cardioverter-defibrillators (ICDs) for all patients with symptomatic heart failure and low left ventricular ejection fraction, but many may not benefit from them.
  • The study evaluated the feasibility of using the MADIT-II-based Risk Stratification Score (MRSS) to differentiate patients and gauge their likely survival benefits from ICDs.
  • Results indicated that among 2,177 patients, different MRSS risk groups had varying survival benefits from ICDs, suggesting that this score can help identify who might actually benefit from prophylactic ICD implantation.
View Article and Find Full Text PDF

Introduction: The implantable cardioverter defibrillator (ICD) is effective for the prevention of sudden cardiac death (SCD) in patients with heart failure and a reduced ejection fraction (HFrEF). The benefit of the ICD in patients with advanced CKD, remains elusive. Moreover, the benefit of the ICD in patients with advanced chronic kidney disease (CKD) and HFrEF who are cardiac resynchronization therapy (CRT) recipients may be attenuated.

View Article and Find Full Text PDF
Article Synopsis
  • Both selective (metoprolol) and nonselective (carvedilol) beta-blockers are used for heart failure (HF), but their impact on rhythm issues in patients with implantable cardioverter-defibrillators (ICD) is not well studied.
  • * This research compared the effects of metoprolol and carvedilol on atrial tachyarrhythmia (ATA) and ventricular arrhythmia (VA) in HF patients with an ICD using data from five major trials.
  • * Results showed that carvedilol was linked to a significantly lower risk of ATA and inappropriate ICD shocks compared to metoprolol, while also suggesting a slight reduction in fast VA risk, although this last finding wasn’t
View Article and Find Full Text PDF

Background And Aims: De novo implanted cardiac resynchronization therapy with defibrillator (CRT-D) reduces the risk of morbidity and mortality in patients with left bundle branch block, heart failure and reduced ejection fraction (HFrEF). However, among HFrEF patients with right ventricular pacing (RVP), the efficacy of CRT-D upgrade is uncertain.

Methods: In this multicentre, randomized, controlled trial, 360 symptomatic (New York Heart Association Classes II-IVa) HFrEF patients with a pacemaker or implantable cardioverter defibrillator (ICD), high RVP burden ≥ 20%, and a wide paced QRS complex duration ≥ 150 ms were randomly assigned to receive CRT-D upgrade (n = 215) or ICD (n = 145) in a 3:2 ratio.

View Article and Find Full Text PDF
Article Synopsis
  • Congenital Long QT Syndrome (LQTS) is a genetic heart condition, and researchers investigated how well current genetic variant annotation tools predict cardiac risks in LQTS patients.
  • Among 2025 patients studied, different algorithms showed varying success in identifying pathogenic mutations, with REVEL performing best at 100%.
  • Despite these tools accurately identifying variants, they failed to predict cardiac events or life-threatening scenarios, highlighting the need to focus on mutation location and function for assessing risks associated with LQTS.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the use of Left Ventricular Assist Devices (LVAD) in advanced heart failure patients, particularly those with a history of ventricular tachyarrhythmia (VTA), and aims to improve outcomes through a new intra-operative ablation protocol.
  • Researchers designed a randomized clinical trial involving 100 LVAD candidates, comparing those receiving intra-operative VTA ablation against those receiving standard medical management.
  • The trial will track various outcomes for an average of 18 months post-surgery, assessing VTA recurrence, adverse events, right heart function, healthcare utilization, and quality of life.
View Article and Find Full Text PDF
Article Synopsis
  • Black Americans with nonischemic cardiomyopathy (NICM) have a higher risk of tachyarrhythmias and complications related to implantable cardioverter-defibrillators (ICDs) compared to White Americans.
  • The study found that Black patients were younger, more likely to be female, and had more comorbidities, contributing to their increased risk for first ventricular tachyarrhythmias and ICD therapies.
  • Despite the higher risks in NICM cases, both Black and White patients showed similar benefits from ICDs in ischemic cardiomyopathy.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) on atrial tachyarrhythmias (ATA) in patients with cardiac implantable electronic devices (CIEDs), revealing a notable reduction in ATA hospitalizations linked to SGLT2i use.
  • - Analyzing data from 13,888 patients over 24,442 years of follow-up, results show a 22% decrease in ATA risk and all-cause mortality among SGLT2i users, particularly in heart failure patients, but no significant effect on ventricular tachyarrhythmias (VTA).
  • - The findings suggest that SGLT2i can significantly lower ATA and mortality
View Article and Find Full Text PDF
Article Synopsis
  • * This study analyzed data from 2938 patients across five international registries, focusing on the link between adrenergic (AD) and nonadrenergic (non-AD) triggered syncopal events and subsequent life-threatening risks.
  • * Results showed that AD-triggered syncope significantly increased the risk of future life-threatening events, with a hazard ratio of 7.61, while non-AD triggered events did not show a significant risk increase.
View Article and Find Full Text PDF

Background: Studies of outcome differences by sex in out-of-hospital cardiac arrest (OHCA) have produced mixed results that may depend on age, a potential surrogate for menopausal status.

Objective: We used quantitative measures of ventricular fibrillation (VF) waveforms - indicators of the myocardium's physiology - to assess whether survival differences according to sex and age group may be mediated via a biologic mechanism.

Methods: We conducted a cohort study of VF-OHCA in a metropolitan EMS system.

View Article and Find Full Text PDF